XML 55 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Reinsurance (Tables)
12 Months Ended
Dec. 31, 2019
Reinsurance Disclosures [Abstract]  
Ceded reinsurance
Assumed, ceded and net amounts for the years ended December 31, 2019, 2018 and 2017 were as follows (in thousands of U.S. dollars): 
 
 
Premiums
Written
 
Premiums
Earned
 
Losses and Loss
Expenses
2019
 
 
 
Non-life (1)
 
$
5,792,542

 
$
5,433,357

 
$
3,879,242

Life and Health
 
1,492,778

 
1,489,721

 
1,277,684

Assumed
 
$
7,285,320

 
$
6,923,078

 
$
5,156,926

 
 
 
 
 
 
 
Non-life (1)
 
$
353,735

 
$
375,301

 
$
219,102

Life and Health
 
22,527

 
22,559

 
14,668

Ceded
 
$
376,262

 
$
397,860

 
$
233,770

 
 
 
 
 
 
 
Non-life (1)
 
$
5,438,807

 
$
5,058,056

 
$
3,660,140

Life and Health
 
1,470,251

 
1,467,162

 
1,263,016

Net
 
$
6,909,058

 
$
6,525,218

 
$
4,923,156


 
 
Premiums
Written
 
Premiums
Earned
 
Losses and Loss
Expenses
2018
 
 
 
Non-life
 
$
5,064,780

 
$
4,751,958

 
$
3,566,201

Life and Health
 
1,235,149

 
1,235,973

 
1,035,363

Assumed
 
$
6,299,929

 
$
5,987,931

 
$
4,601,564

 
 
 
 
 
 
 
Non-life
 
$
472,498

 
$
450,096

 
$
397,554

Life and Health
 
24,067

 
24,025

 
10,755

Ceded
 
$
496,565

 
$
474,121

 
$
408,309

 
 
 
 
 
 
 
Non-life
 
$
4,592,282

 
$
4,301,862

 
$
3,168,647

Life and Health
 
1,211,082

 
1,211,948

 
1,024,608

Net
 
$
5,803,364

 
$
5,513,810

 
$
4,193,255

 
 
Premiums
Written
 
Premiums
Earned
 
Losses and Loss
Expenses
2017
 
 
 
Non-life
 
$
4,604,938

 
$
4,483,662

 
$
3,644,844

Life and Health
 
982,956

 
987,884

 
813,446

Assumed
 
$
5,587,894

 
$
5,471,546

 
$
4,458,290

 
 
 
 
 
 
 
Non-life
 
$
450,129

 
$
428,471

 
$
639,277

Life and Health
 
17,839

 
18,094

 
(21,969
)
Ceded
 
$
467,968

 
$
446,565

 
$
617,308

 
 
 
 
 
 
 
Non-life
 
$
4,154,809

 
$
4,055,191

 
$
3,005,567

Life and Health
 
965,117

 
969,790

 
835,415

Net
 
$
5,119,926

 
$
5,024,981

 
$
3,840,982

 
(1)
Non-life Losses and loss expenses include amounts allocated to Corporate and Other as disclosed in Note 18.